The Decibel Can GLP-1s do for opioid addiction what they did for weight loss?
13 snips
Nov 2, 2026 
Alanna Smith, a Globe and Mail health reporter covering medical research and public health, explores whether GLP-1 medications could quiet “drug noise” as they do food cravings. She discusses promising animal and observational research, a Canadian clinical trial, off-label use in rehab, and concerns about malnutrition, anhedonia, relapse, access and whether these drugs can ever replace holistic addiction care.
AI Snips
Chapters
Transcript
Episode notes
Could GLP-1s Quiet Drug Noise
- GLP-1s may reduce addiction-related cravings by altering dopamine pathways tied to reward, motivation, and desire.
- Researchers ask whether the medications can quiet “drug noise” as they appear to quiet “food noise.”
GLP-1s Could Expand Opioid Treatment
- GLP-1s could complement, not replace, effective opioid treatments such as buprenorphine and methadone.
- Their appeal includes potentially blunting cravings across multiple drug classes while expanding limited treatment options.
The Biggest GLP-1 Opioid Trial Is Still Years Away
- Evidence remains strongest for alcohol use disorder and animal studies, while opioid research is still developing.
- A Canadian randomized trial is testing an experimental GLP-1 alongside buprenorphine in 465 participants.